Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.

ABSTRACT:

Purpose

Retrospective analysis of irAEs in melanoma patients treated with nivolumab.

Experimental design

Data were pooled from 148 patients (33 resected, 115 unresectable) treated with nivolumab plus peptide vaccine or nivolumab alone every 2 weeks for 12 weeks. Patients with stable disease or regression received an additional 12-week cycle, then nivolumab alone every 12 weeks for up to 2 additional years. Frequency, grade, and characteristics of immune-related adverse events (irAE) were analyzed. A 12-week landmark survival analysis using a multivariate time-dependent Cox proportional hazard model assessed difference in overall survival (OS) in the presence or absence of irAEs.

Results

IrAEs of any grade were observed in 68.2% of patients (101 of 148). Grade III/IV i

SUBMITTER: Freeman-Keller M 

PROVIDER: S-EPMC4755809 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature